-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics. - More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FECD. - Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology. - The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Product Insights
Spinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Lung Adenocarcinoma Drug Details: Trametinib (GSK1120212,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Ovarian Cancer Drug Details: Trametinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Peritoneal Cancer Drug Details: Trametinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in High-Grade Glioma Drug Details: Trametinib...